From April 9 – April 13, 2018, Philadelphia, PA was the host city for the 12th Annual Workshop on Recent Issues in Bioanalysis (WRIB). This conference brings together representatives of small and large pharmaceutical companies, regulators from around the world and toxicology and bioanalytical providers. AIT Bioscience was fortunate to have representation from three of our colleagues, Jennifer Vance, Ashley Brant and Cameron Brown. These three attended the main workshop focused on LC-MS/MS, hybrid LBA-LC/MS/MS, and LBA approaches to bioanalysis as well as full-day short courses on Biomarkers and Internal Standard Response Challenges.
Presentation topics ranged from re-visiting the learnings obtained from a decade of incurred sample reproducibility to future applications of automation and the use of LC-MS/MS in anti-drug antibody analysis. As is tradition, the afternoon of Day 2 was dedicated to the regulators and featured talks from US FDA, Health Canada, UK MHRA, Japan MHLW-NIHS and panel representation from EMA, ANVISA and Finland Fimea. Significant discussion focused on the characterization of biomarkers from both a bioanalytical as well as a clinical perspective as well as questions regarding the status of a finalized FDA Bioanalytical Guidance and the ICH M10.
The conference additionally featured 3 days of poster sessions, including AIT Bioscience’s poster, “Measurement of Lidocaine and 2,6-DMA in Minipig Plasma, Skin, and Dermal Tapes Using UHPLC with Electrospray MS/MS” detailing 5 different methods for the low-level analysis of lidocaine and one of its key metabolites in challenging matrices.